Sapient Capital LLC Has $1.61 Million Stock Position in Astrazeneca Plc $AZN

Sapient Capital LLC lifted its holdings in shares of Astrazeneca Plc (NYSE:AZN) by 136.7% during the second quarter, Holdings Channel.com reports. The firm owned 8,592 shares of the company’s stock after acquiring an additional 4,962 shares during the quarter. Sapient Capital LLC’s holdings in Astrazeneca were worth $1,608,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the business. Allied Private Wealth LLC bought a new position in Astrazeneca during the 2nd quarter worth $35,000. Oliver Luxxe Assets LLC bought a new stake in shares of Astrazeneca in the 2nd quarter valued at about $8,518,000. Avity Investment Management Inc. grew its position in shares of Astrazeneca by 14.6% in the 2nd quarter. Avity Investment Management Inc. now owns 2,635 shares of the company’s stock valued at $500,000 after buying an additional 335 shares during the last quarter. Windsor Capital Management LLC acquired a new stake in shares of Astrazeneca in the second quarter valued at about $671,000. Finally, Legacy Wealth Management LLC MS acquired a new stake in shares of Astrazeneca in the second quarter valued at about $308,000. Institutional investors own 20.35% of the company’s stock.

Astrazeneca Stock Up 0.2%

Shares of NYSE AZN opened at $161.80 on Tuesday. Astrazeneca Plc has a 12-month low of $145.79 and a 12-month high of $212.71. The company has a quick ratio of 0.67, a current ratio of 0.89 and a debt-to-equity ratio of 0.47. The firm has a market cap of $250.94 billion, a PE ratio of 24.19, a P/E/G ratio of 1.39 and a beta of 0.26. The company’s fifty day simple moving average is $175.98 and its 200 day simple moving average is $186.98.

Astrazeneca (NYSE:AZN) last announced its quarterly earnings data on Monday, July 27th. The company reported $2.63 earnings per share for the quarter, beating the consensus estimate of $2.50 by $0.13. The firm had revenue of $15.38 billion for the quarter, compared to analyst estimates of $15.44 billion. Astrazeneca had a net margin of 17.02% and a return on equity of 31.45%. During the same quarter in the prior year, the business earned $2.17 earnings per share. The business’s quarterly revenue was up 6.4% compared to the same quarter last year. As a group, sell-side analysts forecast that Astrazeneca Plc will post 10.22 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on AZN shares. Bank of America reaffirmed a “buy” rating on shares of Astrazeneca in a research note on Wednesday, July 1st. The Goldman Sachs Group reissued a “buy” rating on shares of Astrazeneca in a research report on Wednesday, July 1st. Sanford C. Bernstein restated a “buy” rating on shares of Astrazeneca in a report on Monday, May 4th. Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of Astrazeneca in a research report on Tuesday, June 30th. Finally, Weiss Ratings lowered shares of Astrazeneca from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, July 28th. Twelve research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Astrazeneca currently has a consensus rating of “Moderate Buy” and a consensus target price of $211.00.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.